CUE - Company ID 0001645460
The table below shows Cue Biopharma, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$10.94M | -$8.17M | -$9.78M | -$10.83M | -$11.57M | -$11.79M |
| Capital expenditure | $121.00K | $150.00K | $55.00K | $0.00 | $27.00K | $648.00K |
| Investing cash flow | -$121.00K | -$150.00K | -$55.00K | $15.00M | -$27.00K | $9.35M |
| Dividends paid | - | - | - |
Cue Biopharma, Inc. reported operating cash flow of -$21.69M for fiscal year 2025. That is up 40.3% from -$36.33M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$12.14M (FY 2017) to -$21.69M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | $0.00 | $191.00K | $85.00K |
| Financing cash flow | $306.00K | -$1.00M | $2.35M | $388.00K | $15.16M | $834.00K |